AstraZeneca PLC (AZN)vsNextera Energy Inc (NEE)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
NEE
Nextera Energy Inc
$93.10
-0.24%
UTILITIES · Cap: $194.60B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 117% more annual revenue ($60.44B vs $27.87B). NEE leads profitability with a 29.4% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.52. NEE earns a higher WallStSmart Score of 67/100 (B-).
AZN
Buy62
out of 100
Grade: C+
NEE
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Intrinsic value data unavailable for NEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Strong operational efficiency at 30.2%
Earnings expanding 160.0% YoY
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Elevated debt levels
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : NEE
The strongest argument for NEE centers on Operating Margin, EPS Growth, Market Cap. Profitability is solid with margins at 29.4% and operating margin at 30.2%.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : NEE
The primary concerns for NEE are PEG Ratio, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.75 is elevated, increasing financial risk.
Key Dynamics to Monitor
NEE carries more volatility with a beta of 0.72 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NEE scores higher overall (67/100 vs 62/100), backed by strong 29.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nextera Energy Inc
UTILITIES · UTILITIES - REGULATED ELECTRIC · USA
NextEra Energy, Inc. is an American energy company with about 46 gigawatts of generating capacity, revenues of over $17 billion in 2017, and about 14,000 employees throughout the US and Canada. Its subsidiaries include Florida Power & Light (FPL), NextEra Energy Resources, NextEra Energy Partners, Gulf Power Company, and NextEra Energy Services.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?